Nervous System News and Research RSS Feed - Nervous System News and Research

The nervous system is an organ system containing a network of specialized cells called neurons that coordinate the actions of an animal and transmit signals between different parts of its body. In most animals the nervous system consists of two parts, central and peripheral. The central nervous system contains the brain and spinal cord.
New NEI study shows that microglia can accelerate damage wrought by blinding eye disorders

New NEI study shows that microglia can accelerate damage wrought by blinding eye disorders

Spider-like cells inside the brain, spinal cord and eye hunt for invaders, capturing and then devouring them. These cells, called microglia, often play a beneficial role by helping to clear trash and protect the central nervous system against infection. But a new study by researchers at the National Eye Institute (NEI) shows that they also accelerate damage wrought by blinding eye disorders, such as retinitis pigmentosa. [More]
Wayne State University awarded grant to explore new MS pathology model

Wayne State University awarded grant to explore new MS pathology model

The National Multiple Sclerosis Society has provided a grant to a Wayne State University School of Medicine professor to explore a new model of MS pathology. [More]
Robert G. Miller awarded $1.5 million grant to help fund Neuraltus' Phase 2 clinical study of NP001 for ALS

Robert G. Miller awarded $1.5 million grant to help fund Neuraltus' Phase 2 clinical study of NP001 for ALS

Neuraltus Pharmaceuticals, Inc., a privately-held biopharmaceutical company focused on the development of groundbreaking drugs to treat neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), announced today that Robert G. Miller, M.D., Director of the Forbes Norris MDA/ALS Research Center at Sutter Health's California Pacific Medical Center in San Francisco, has been awarded a grant from The ALS Association for $1.5 million to help fund a Phase 2 clinical study of the company's investigational therapy for ALS, NP001. [More]

Genpact, UCB receive Aecus Innovation Award for collaboration in driving global business services

UCB, a multinational biopharmaceutical company, and Genpact, a global leader in designing, transforming, and running intelligent business operations, have received the Aecus Innovation Award in recognition of their close collaboration in driving transformation that achieved far-reaching operational efficiencies in UCB's global business services (GBS) finance organization. [More]
Pharma Two B reports positive results from P2B001 Phase IIb study for treatment of early stage PD

Pharma Two B reports positive results from P2B001 Phase IIb study for treatment of early stage PD

Pharma Two B Ltd., a privately held company developing innovative therapeutics based on previously approved drugs, announced today the successful results of the company's Phase IIb pivotal study of P2B001 for the treatment of early stage Parkinson's Disease (PD). [More]
TSRI scientists find five different miRNAs involved in memory formation

TSRI scientists find five different miRNAs involved in memory formation

Scientists from the Florida campus of The Scripps Research Institute (TSRI) have found that a type of genetic material called “microRNA” plays surprisingly different roles in the formation of memory in animal models. In some cases, these RNAs increase memory, while others decrease it. [More]
Three National Laureates selected for 2015 Blavatnik National Awards for Young Scientists

Three National Laureates selected for 2015 Blavatnik National Awards for Young Scientists

A chemist who has made important discoveries in both the human brain and sustainable energy, a neurosurgeon who has done pioneering work mapping the "blueprint" of how humans speak and hear, and a computer scientist who has changed our understanding of the capacity of wireless networks are the three winners of the 2015 Blavatnik National Awards for Young Scientists. [More]
New research reveals that male and female mice use different cells to process pain

New research reveals that male and female mice use different cells to process pain

New research released today in Nature Neuroscience reveals for the first time that pain is processed in male and female mice using different cells. These findings have far-reaching implications for our basic understanding of pain, how we develop the next generation of medications for chronic pain—which is by far the most prevalent human health condition—and the way we execute basic biomedical research using mice. [More]
Study may lead to better treatments for children with neuroblastoma

Study may lead to better treatments for children with neuroblastoma

Researchers studying the pediatric cancer neuroblastoma have detailed how cancer-driving mutations evolve during chemotherapy, and they hope to exploit this knowledge to design better treatments for children. [More]

Tiny aquatic flatworms could replace existing animal models used in neurotoxicity tests

Laboratories that test chemicals for neurological toxicity could reduce their use of laboratory mice and rats by replacing these animal models with tiny aquatic flatworms known as freshwater planarians. [More]
Inhibikase Therapeutics receives Phase II SBIR grant to advance novel RAMP medicinal chemistry program

Inhibikase Therapeutics receives Phase II SBIR grant to advance novel RAMP medicinal chemistry program

Inhibikase Therapeutics, Inc. announces the receipt of a Phase II SBIR grant in the amount of $1.54 million dollars from the U.S. National Institutes of Health to advance its novel Re-engineering with Metabolism Preserved (RAMP) medicinal chemistry program. [More]
Spinifex Pharmaceuticals enters into agreement to be acquired by Novartis

Spinifex Pharmaceuticals enters into agreement to be acquired by Novartis

Spinifex Pharmaceuticals, Inc., a company focused on the development of new drugs for the treatment of chronic pain, today announces that it has agreed to the sale of Spinifex to Novartis International AG, for an upfront cash consideration of US$200 million plus undisclosed clinical development and regulatory milestone payments. [More]
Neuralstem's HK532-IGF-1 neural stem cells therapy for Alzheimer's disease presented at ISSCR Annual Meeting

Neuralstem's HK532-IGF-1 neural stem cells therapy for Alzheimer's disease presented at ISSCR Annual Meeting

Neuralstem, Inc., a biopharmaceutical company using neural stem cell technology to develop small molecule and cell therapy treatments for central nervous system diseases, announced that the poster "Human Neural Stem Cells Expressing IGF-1: A Novel Cellular Therapy for Alzheimer's Disease" was presented yesterday at the International Society for Stem Cell Research (ISSCR) Annual Meeting in Stockholm, Sweden. [More]
Hartmuth Kolb named recipient of 2015 Alzheimer Award

Hartmuth Kolb named recipient of 2015 Alzheimer Award

The Journal of Alzheimer's Disease is proud to announce that Hartmuth Kolb, PhD, Head of Neuroscience Biomarkers, Johnson & Johnson, San Diego, CA, has been chosen as the recipient of the 2015 Alzheimer Award presented by the Journal of Alzheimer's Disease in recognition of his outstanding work on the importance and imaging of neurofibrillary tangles (NFTs) and Alzheimer's disease (AD). [More]
Innovative gene transfer-based treatment for kids with giant axonal neuropathy

Innovative gene transfer-based treatment for kids with giant axonal neuropathy

University of North Carolina School of Medicine researchers have developed an innovative, experimental gene transfer-based treatment for children with giant axonal neuropathy (GAN). [More]
Errors on memory and thinking tests may signal Alzheimer's 18 years before diagnosis

Errors on memory and thinking tests may signal Alzheimer's 18 years before diagnosis

A new study suggests that errors on memory and thinking tests may signal Alzheimer's up to 18 years before the disease can be diagnosed. The research is published in the June 24, 2015, online issue of Neurology, the medical journal of the American Academy of Neurology. [More]
Impax Laboratories prices convertible senior notes due 2022 in private offering

Impax Laboratories prices convertible senior notes due 2022 in private offering

Impax Laboratories, Inc. priced $500,000,000 aggregate principal amount of 2.00% convertible senior notes due 2022 (the "notes") in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). [More]
Cell transplantation researchers successfully treat laboratory rats modeled with severe burns

Cell transplantation researchers successfully treat laboratory rats modeled with severe burns

Cell transplantation researchers have successfully used bone marrow-derived mesenchymal stromal cells (MSCs) to treat a variety of diseases and conditions. Now, using injections of MSCs, a research team in Brazil has successfully treated laboratory rats modeled with severe burns. [More]
Brainpaths neurological device stimulates brain‘s sensory cortex

Brainpaths neurological device stimulates brain‘s sensory cortex

Brainpaths is a BREAKTHROUGH: a Neurological Medical Device that stimulates the sensory cortex of the brain; Brainpaths Medical Device is non-powered, approved for home use and can be purchased without a prescription for under $40. [More]
OhioHealth Neuroscience Center launched at Riverside Methodist Hospital

OhioHealth Neuroscience Center launched at Riverside Methodist Hospital

On July 6, 2015, OhioHealth will open its doors to the new OhioHealth Neuroscience Center on Riverside Methodist Hospital's campus. [More]
Advertisement
Advertisement